The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Conflict of interest disclosure in off-label oncology clinical trials.
Blair Billings Irwin
No relevant relationships to disclose
Amy Pickar Abernethy
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Helsinn Therapeutics; Novartis
Research Funding - Alexion Pharmaceuticals; Amgen; BioVex; DARA BioSciences; Endo Pharmaceuticals; Helsinn Therapeutics; Kanglaite Pharmaceutical ; Mi-Co; NCI; NIH/NIA; NIH/NINR; Novartis; RWJ Foundation; US Agency for Healthcare Research and Quality
Bradford Richard Hirsch
No relevant relationships to disclose